Follow-up blood culture 14 days after the end of treatment grew MRSA (vancomycin MIC = 48 1 mg/l) again. At that time the patient complained of back pain and spine MRI revealed 49 infectious spondylitis at T12-L1. Vancomycin was restarted and blood culture became 50 negative nine days later. With receiving vancomycin his back pain was improved and C-51 reactive protein (CRP) decreased to 0.24 mg/dl until 30 days after restart of vancomycin, 52 when back pain was aggravated and CRP suddenly elevated to 8.1 mg/dl. Blood culture grew 53 MRSA with vancomycin MIC higher than 2 mg/l. Confirmative test using E-test method in 54 the clinical microbiology laboratory at the time of isolation revealed that this strain had 55 vancomycin MIC of 3 mg/l. When we re-tested the frozen isolates using broth microdilution 56 test, vancomycin MIC was 4 mg/l. Vancomycin was switched to linezolid and continued for 57 four weeks without any adverse effects. His back pain was improved and CRP decreased to 58 0.03 mg/dl. He has been free of relapse for 3 months now. amplification and sequencing of seven housekeeping genes (arcC, aroE, glpF, gmk, pta, tpi 67 and yqiL) as previously described (5). The allelic profiles and sequence types (ST) were 68 assigned by the MLST web site (http://saureus.mlst.net/). SCCmec types were determined by 69 the multiplex PCR method (13). Isolates were screened for the lukF-PV and lukS-PV genes 70 encoding the components of the Panton-Valentine leukocidin (PVL) toxin as previously 71 described (11). Pulsed-field gel electrophoresis (PFGE) was performed as described 72 previously (17). Both isolates were determined to be PVL-negative ST72 strains and carried 
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All the isolates from the patient displayed the identical pulsotype, whereas they were 79 different from the types of the reference strains (FIG 1) .
80
In order to determine if an original isolate from the patient was heterogeneous VISA 81 (hVISA), we conducted a population analysis profile (PAP) test as previously described (15).
82
The first isolate from the patient was determined to be vancomycin-susceptible S. aureus 83 (VSSA) with no heterogeneous population of VISA, and two isolates of VISA were again 84 confirmed as VISA by this method. Unfortunately, the VSSA (vancomycin MIC, 1 mg/l) 85 isolated at the first relapse of bacteremia was not stored, and so it could not be tested for the 86 presence of heterogeneous population. 
Since the first report of S. aureus with reduced susceptibility to vancomycin (MIC 8 mg/l) 91 from Japan in 1997 (9), there have been increasing reports of VISA and hVISA worldwide. In 
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The VISA isolates in our report showed different vancomycin MICs according to the test 106 methods. The MIC from E-test analysis was lower than that from the broth microdilution 107 method. Such differences in vancomycin MICs of S. aureus according to test method have 108 been previously reported (4).
109
Antecedent vancomycin use and prior MRSA infection two or three months before the 110 current infection have been reported to be independent risk factors for VISA (6). The 
